Table 4.
Safety Profile Among the 32 Patients with EOC Who Were Treated with Anlotinib Combined with PD-1 Blockades
| Adverse Reactions | Total (N, %) | Grade 3–4 (N, %) |
|---|---|---|
| Fatigue | 22 (68.8) | 3 (9.4) |
| Nausea and vomiting | 18 (56.3) | 5 (15.6) |
| Hypertension | 16 (50.0) | 5 (15.6) |
| Diarrhea | 13 (40.6) | 2 (6.3) |
| Rash | 10 (31.3) | 1 (3.1) |
| Pain | 9 (28.1) | 0 (0.0) |
| Hand and foot syndrome | 9 (28.1) | 2 (6.3) |
| Weight loss | 7 (21.9) | 0 (0.0) |
| Hepatotoxicity | 5 (15.6) | 0 (0.0) |
| RCCEP | 4 (12.5) | 0 (0.0) |
| Proteinuria | 4 (12.5) | 1 (3.1) |
| Pneumonia | 3 (9.4) | 0 (0.0) |
| Bleeding | 2 (6.3) | 0 (0.0) |
Abbreviations: EOC, epithelial ovarian cancer; RCCEP, reactive cutaneous capillary endothelial proliferation.